GlassScriptPhysician profile
Miles D Hamm
NPI 1205564960
$5,976.09
in general payments reported to CMS, 2019-2025
42 companies · $2,548 in 2025
The $2,548 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $340 · 2023: $1,520 · 2024: $1,568 · 2025: $2,548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,562 · Education: $74.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,561.55 |
| Education | $74.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $756.37 | 2022-2024 | Caplyta |
| Abbvie INC. | $753.22 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $360.53 | 2022-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Takeda Pharmaceuticals U.S.A., INC. | $343.26 | 2022-2025 | Hyqvia, Trintellix |
| Eisai INC. | $337.91 | 2024-2025 | |
| Janssen Biotech, INC. | $255.33 | 2025 | |
| Axsome Therapeutics, INC. | $229.18 | 2022-2025 | Auvelity, Sunosi |
| Harmony Biosciences LLC | $222.58 | 2025 | |
| Alkermes, INC. | $216.43 | 2022-2024 | Lybalvi, Aristada, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $197.76 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Jazz Pharmaceuticals INC. | $186.75 | 2024-2025 | |
| Corium, LLC | $176.55 | 2023-2024 | Azstarys |
| Pfizer INC. | $166.76 | 2025 | |
| Tris Pharma INC | $150.68 | 2023-2024 | Dyanavel Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2024 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $123.91 | 2024-2025 | Qelbree |
| Lilly USA, LLC | $118.67 | 2025 | Amyvid, Kisunla, Zepbound |
| Neurocrine Biosciences, INC. | $116.04 | 2023-2024 | Ingrezza |
| Sk Life Science, INC. | $108.22 | 2025 | |
| Ironshore Pharmaceuticals INC. | $104.79 | 2022-2024 | Jornay Pm |
| Lundbeck LLC | $94.63 | 2024-2025 | Rexulti, Vyepti |
| Otsuka America Pharmaceutical, INC. | $93.77 | 2023-2025 | Rexulti, Abilify Maintena |
| Avadel Cns Pharmaceuticals, LLC | $93.19 | 2024-2025 | Lumryz |
| Ucb, INC. | $84.20 | 2025 | Briviact, Rystiggo |
| C2n Diagnostics, LLC | $57.54 | 2025 | Precivityad2 |
| Amgen INC. | $55.33 | 2025 | Uplizna |
| Argenx US, INC. | $44.57 | 2025 | Vyvgart Hytrulo |
| Biogen, INC. | $42.30 | 2025 | Leqembi |
| Idorsia Pharmaceuticals US INC | $40.28 | 2023-2024 | Quviviq |
| Neos Therapeutics, LP | $40.15 | 2022-2024 | Adzenys Xr-Odt |
| Zoll Respicardia, INC. | $33.37 | 2025 | Remede System |
| Fisher & Paykel Healthcare INC | $29.46 | 2025 | Fisher & Paykel Healthcare |
| Vanda Pharmaceuticals INC. | $26.88 | 2025 | Fanapt |
| Life Molecular Imaging LTD | $26.77 | 2025 | Neuraceq |
| Noven Therapeutics, LLC | $23.17 | 2024 | Xelstrym |
| Inspire Medical Systems, INC. | $23.00 | 2025 | Inspire |
| Alexion Pharmaceuticals, INC. | $22.06 | 2025 | Ultomiris |
| Livanova USA, INC. | $20.26 | 2025 | Vns Therapy |
| Tanabe Pharma America, INC. | $19.90 | 2025 | Radicava |
| Averitas Pharma INC. | $19.69 | 2025 | Qutenza |
| E.R. Squibb & Sons, L.L.C. | $19.04 | 2024 | Cobenfy |
| Vertical Pharmaceuticals, LLC | $16.59 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miles Hamm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.